Evaluation of efficacy, safety and Product attributes of a test shampoo (Selenium Sulfide 2.5%) in participants with dandruff.

Abbott Healthcare Private Ltd0 个研究点目标入组 30 人开始时间: 待定最近更新: 2023年5月29日

试验速览

暂无简介。

•1. Voluntary men and/or women with moderate Dandruff (score > 10 as per scale mentioned).
•2. Age: 18 to 70 years
•3. Having signed a Consent Form after being informed orally and in writing of all information concerning the study procedures and study objectives.
•4. Ready to comply with the study specifications
•5. Willing to refrain from use of all other topical medications that would affect the results of the trial, including medicated shampoos/oils or antibiotics, during the treatment periods.

•1. Pregnancy by UPT or Lactating women.
•2.History or presence of compromising dermatosis elsewhere on the skin
•3.History or presence of Parkinsons disease, HIV, infections or disorders of the central nervous system
•4. Have used an antidandruff agent in the past 14 days
•5. Presence of any skin condition that would interfere with the diagnosis or assessment of dandruff,e.g., psoriasis, acne, atopic dermatitis
•6. Clinically significant systemic disease (e.g., immunological deficiencies, AIDS, current malignancies, uncontrolled diabetes mellitus)
•7. Use within 1 month prior to baseline of any treatment that would affect the results of the trial, including a) systemic antifungals, b) systemic steroids, c) systemic antibiotics d) systemic anti-inflammatory agents or e) cytostatic or immunomodulating drugs (e.g. cyclosporine, tacrolimus, pimecrolimus) or f) systemic retinoids
•8. Use within 2 weeks prior to baseline of any treatment that would affect the results of the trial, including a) topical steroids, b) topical retinoids, c) topical anti-inflammatory agents, d) topical antibiotics or e) topical treatment of adherent dandruff (e.g., coal tar preparation, antidandruff shampoo or oils or gels or creams or conditioners, f) antihistamines.
•9. Participant in an exclusion period or already participating in another similar cosmetic or therapeutic trial as identified during screening on visit 1 (V1).
•10. Actinically damaged skin

发起方

Abbott Healthcare Private Ltd